Department of Internal Medicine, Okayama Rosai Hospital, Japan.
Department of Respiratory Medicine, Okayama Rosai Hospital, Japan.
Intern Med. 2022 Aug 15;61(16):2523-2526. doi: 10.2169/internalmedicine.9136-21. Epub 2022 May 31.
A patient with follicular lymphoma treated with obinutuzumab and bendamustine experienced prolonged coronavirus disease-2019 (COVID-19). One month after the symptoms transiently improved, the patient experienced exacerbated COVID-19 symptoms. The patient recovered from COVID-19 with remdesivir and dexamethasone and was discharged 77 days after the disease onset. The patient completed a primary series of SARS-CoV-2 vaccinations on day 176, but the anti-spike protein IgG was not detected later. A careful observation to detect any subsequent relapse of COVID-19 symptoms is necessary in immunocompromised patients. Chemotherapy should be based on the disease status and type of lymphoma.
一位滤泡性淋巴瘤患者在接受奥滨尤妥珠单抗和苯达莫司汀治疗后出现了 COVID-19 持续感染。在症状短暂改善一个月后，患者出现了 COVID-19 症状恶化。患者使用瑞德西韦和地塞米松治疗后康复，并在发病后 77 天出院。患者在第 176 天完成了 SARS-CoV-2 疫苗的基础系列接种，但后来未检测到抗刺突蛋白 IgG。对于免疫功能低下的患者，需要仔细观察以检测任何随后 COVID-19 症状的复发。化疗应基于疾病状态和淋巴瘤类型。
